Skip to content
Menu

BeOne Medicines AG ONC

Full chart Compare
Set alert

Price alert · ONC

All alert types
395.95 USD -3.75 (-0.94%)

As ofNov 20, 2026, 12:28 PM EST

385.00 Day range 399.76
253.95 52-week range 424.73
YTD
+30.33%
1 year
+13.36%

Fundamental scorecard

15 of 25 checks passed on ONC’s reported financials

ValueGrowthProfitabilityHealthDividend

15of 25 checks passed

  • Value 1 of 5
  • Growth 5 of 5
  • Profitability 4 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Value 1 of 5

  • No data:P/E below its own 5-year median P/E 49.4. Not enough data to decide.
  • Failed:P/E under 20 P/E 49.4: an earnings yield of 2.0%.
  • Passed:Price to sales below its own 5-year median Price to sales 6.8 against a 5-year median of 7.7.
  • Failed:Price to book below its own 5-year median Price to book 7.8 against a 5-year median of 5.3.
  • Failed:Free cash flow yield above 4% Free cash flow of 1.47B is 3.2% of the market value.

Growth 5 of 5

  • Passed:Revenue grew over the last year Revenue of 6.61B is +32.9% on the 12 months before.
  • Passed:Revenue grew more than 5% a year over five years +76.8% a year from FY 2020 to FY 2025.
  • Passed:Earnings per share grew over the last year EPS 0.60 against 0.03 in the 12 months before.
  • Passed:Earnings per share grew more than 5% a year over five years EPS -1.50 in FY 2020, 0.19 in FY 2025.
  • Passed:Analysts expect higher earnings per share over the next year The average forward estimate is +38.3% on the last 12 months.

Profitability 4 of 5

  • Passed:Profitable over the last year Net income of 916M over the last 12 months.
  • Failed:Profitable in each of the last five fiscal years A profit in 1 of the last 5 fiscal years.
  • Passed:Return on equity above 15% Return on equity of 18.4%.
  • Passed:Net margin above its 5-year average Net margin of 13.9% against a 5-year average of -62.6%.
  • Passed:Free cash flow is at least 80% of net income Free cash flow of 1.47B is 160.5% of net income.

Financial health 5 of 5

  • Passed:Short-term assets cover short-term liabilities Short-term assets of 7.93B against short-term liabilities of 2.23B.
  • Passed:Short-term assets cover long-term liabilities Short-term assets of 7.93B against long-term liabilities of 1.82B.
  • Passed:Net debt under 40% of equity More cash than debt: 5.78B of cash against 2.06B of debt.
  • Passed:Operating cash flow covers at least 20% of debt Operating cash flow of 1.59B is 77.1% of debt.
  • Passed:Operating profit covers interest at least 3 times Operating profit is 7.1 times the interest expense.

Dividend 0 of 5

  • Failed:Pays a dividend No dividend paid.
  • Failed:Yield above 1.5% No dividend paid.
  • Failed:Pays out under 75% of profit No dividend paid.
  • Failed:Covered by free cash flow No dividend paid.
  • Failed:Not cut in the last five fiscal years No dividend paid.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What ONC owns and owes, as of Sep 30, 2026

Short term and long term

Balance sheet · 9.88B of assets

Debt, equity and cash by year

Now: 3.72B more cash than debt

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

7.16 Safe zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

6 / 9 Average

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

B3 / 5 overall

  • DCF 1
  • Return on Equity 4
  • Return on Assets 5
  • Debt / Equity 3
  • P/E 3
  • P/B 1

Valuation

P/E 116×
P/S 6.2×
P/B 7.6×
P/FCF 35.2×
EV/EBITDA 49.6×
EV/Sales 5.7×
FCF Yield 2.8%

Profitability

Gross Margin 87.5%
Operating Margin 8.4%
Net Margin 5.4%
ROE 6.6%
ROIC 4.7%
ROA 3.5%

Growth (YoY)

Revenue 40.2%
Operating Income 178.7%
EPS (diluted) 141.3%
Free Cash Flow 240.6%

Financial Health

Current Ratio 3.4×
Quick Ratio 3.1×
Debt / Equity 0.5×
Net Debt / EBITDA -4.1×
Interest Coverage 7.7×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2025-12-31